Skip to main content

Result releasedAnnolyse analysis published

Underlying EBITDA up 2.7% but reported result swung to NZ$17.1m NPAT loss

Operating cash flow surged on a NZ$101m receivables collection while items below EBITDA pushed PBT down 160.3% to a NZ$19.5m loss.

OCA revenue trajectory

Revenue context before the current result.

Loading chart...
HY25 was $132.6m, versus $131.6m in HY24.

OCA EBITDA margin

EBITDA margin across covered periods.

Loading chart...
  • HY24 OCA HY: Outside range low ebitda margin. 28.6%; 3-period range 29.1% to 31.7%. EBITDA margin: 28.6%, below normal range; 3-period mean 30.8%, range 29.1%-31.7%.
EBITDA margin: 28.6%, below normal range; 3-period mean 30.8%, range 29.1%-31.7%.

OCA operating cash flow

Operating cash flow across covered periods.

Loading chart...
HY25 was $70.4m, versus $48m in HY24.

OCA NPAT trajectory

Statutory profit after tax across covered periods.

Loading chart...
HY25 was -$17.1m, versus $35.2m in HY24.

Market context

Valuation

These ratios pair a market close from around the result date with verified filing data. An unavailable metric means the required inputs were missing or unsuitable for comparison.

Prices as at close, 4 September 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$579.4m

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

11.06x

i

Recent market cap compared with trailing earnings.

EPS

0.07

i

Recent filing-derived earnings per share.

PEG

Not available

i

Not available for this company right now.

EV/EBITDA

13.37x

i

Enterprise value compared with recent EBITDA.

P/FCF

Not available

i

Not meaningful when free cash flow is negative or unavailable.

P/B

0.51x

i

Market value compared with latest reported equity.

Income and investment-company measures

Yield and investment-company valuation where supported.

Dividend yield

0.0%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Release date
22 November 2024
Published
22 April 2026

Key metrics

Numbers worth scanning first

HY25 vs HY24

Revenue

$132.6m

Caveat: metric quality flags apply; use this value with basis context.

EBITDA

$38.6m

Caveat: metric quality flags apply; use this value with basis context.

Net profit after tax

−$17.1m

Caveat: metric quality flags apply; use this value with basis context.

Net cash inflow from operating activities

$70.4m

Caveat: metric quality flags apply; use this value with basis context.

Declared dividend per share

0.0c

Caveat: metric quality flags apply; use this value with basis context.

Profit before tax

−$19.5m

Caveat: metric quality flags apply; use this value with basis context.

Cash and cash equivalents

$13m

+26.6% ↑ vs $10.3m

Total assets

$2.8b

Caveat: metric quality flags apply; use this value with basis context.

Analysis ofOCA HY25Result releasedAnnolyse analysis published

What changed

Reported earnings swung to a loss despite a small operating gain

Revenue rose 0.8% to NZ$132.6m and underlying EBITDA rose 2.7% to NZ$38.6m, but PBT fell 160.3% from NZ$32.4m profit to a NZ$19.5m loss, and NPAT fell 148.5% from NZ$35.2m profit to a NZ$17.1m loss. Annolyse's historical baseline classifies both PBT and NPAT growth at the lower edge of the recent three-period range (PBT range -197.2% to 199.4%; NPAT range -165.3% to 245.7%), so this is a large negative versus precedent.

Operating cash flow moved the other way, rising 46.6% to NZ$70.4m. The driver is a NZ$101.1m collapse in trade debtors from NZ$121.5m to NZ$20.4m, with debtor days falling from 168 to 28 (within the historical range; the prior comparable was the unusual point).

What matters

The headline loss sits below EBITDA, not in trading

  • Revenue and underlying EBITDA both grew modestly, but depreciation, financing and fair-value items below EBITDA turned a NZ$32.4m PBT into a NZ$19.5m loss — a NZ$51.9m swing on essentially flat operating activity. PBT is the cleaner read here because the effective tax rate flipped from -8.6% (a benefit) to +12.5% (an expense), narrowing the NPAT decline relative to PBT by 11.8 percentage points. For an investor, this means the deterioration is real at the IFRS level but does not show up in the underlying EBITDA management chooses to highlight.
  • Cash conversion looks strong but is balance-sheet-assisted. OCF/EBITDA jumped to 182.0% from 127.5%, almost entirely on the NZ$101.1m receivables release. Strip that out and the underlying cash run-rate is closer to last year's, not 46.6% higher. This matters because the NZ$70.4m headline cash inflow will not recur on the same basis once the working-capital normalisation has played through.
  • Leverage is unchanged at a high level. Net debt sits at NZ$628.9m and net debt to EBITDA is 16.3x, essentially flat versus 16.2x in the prior comparable. Management cites gearing of 37.5% versus 38.3% at FY24, but on an earnings-coverage basis there is no improvement. Debt reduction is a stated strategic priority, but this period did not deliver it.

Expectations

No formal earnings targets are supplied, and the release frames priorities qualitatively — strategic sales, sales cadence, debt reduction, "right sizing"

The supplied second-half shape shows HY24 contributed 49.6% of FY24 revenue, 45.6% of FY24 EBITDA, and 111.7% of FY24 NPAT, implying the FY24 second half was loss-making at the bottom line (-NZ$3.7m implied 2H NPAT). Annualising HY25 revenue gives NZ$265.2m, broadly in line with FY24's NZ$265.5m.

The read is that flat top-line plus a loss-making 1H sets a low bar for FY25 reported NPAT, and the result does not yet show traction on the company's stated FY25 sales focus.

Quality of result

Underlying EBITDA growth of 2.7% on 0.8% revenue growth implies a small operating-leverage gain that looks durable, and the Care segment result improved to NZ$8.6m from NZ$2.1m

Beyond that, the quality signals are mixed.

Payout ratio versus pre-lease FCF is suppressed because the source-backed cash-dividend bridge is unavailable.

Unresolved

Open questions

What specific items below EBITDA — depreciation, financing costs, or fair-value movements on investment property — drove the NZ$51.9m swing in PBT?
Why did trade debtors fall NZ$101.1m, and was this the settlement of prior new-sale receivables that will not recur?
How much of the FY25 EBITDA target is dependent on second-half new-sale volumes given management's stated sales-cadence concerns?
Why has net debt to EBITDA at 16.3x not improved despite the OCF uplift, and what is the path to the stated debt-reduction objective?
When does management expect reported NPAT to return to profit, and on what assumptions?

This briefing cannot assess the composition of items below EBITDA or the sustainability of the receivables collection without the detailed fair-value and segment-cash disclosures.

Ask about OCA HY25

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Oceania Healthcare's HY25 result.

What specific items below EBITDA — depreciation, financing costs, or fair-value movements on investment property — drove the NZ$51.9m swing in PBT?Why does "The headline loss sits below EBITDA, not in trading" matter?How strong was the cash and earnings quality in HY25?What should I watch next for OCA after HY25?

Checking account...

Data appendix

Show segment detail

Open to load segment breakdown.

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

Prior comparable period

Full-year context

Release context

Annual Meeting - CEO Address

HY25 / commentary

Annual Meeting - Chair Address

HY25 / commentary

Annual Meeting - Presentation

HY25 / commentary

Get notified when OCA publishes next

Get the next Oceania Healthcare briefing and related NZX reporting-season updates by email.